Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.67 Insider Own62.86% Shs Outstand55.14M Perf Week-14.57%
Market Cap116.39M Forward P/E- EPS next Y-1.18 Insider Trans0.00% Shs Float20.48M Perf Month-7.05%
Income-92.28M PEG- EPS next Q-0.36 Inst Own31.53% Short Float24.20% Perf Quarter-50.00%
Sales4.94M P/S23.56 EPS this Y29.13% Inst Trans0.24% Short Ratio13.40 Perf Half Y11.94%
Book/sh0.75 P/B2.81 EPS next Y7.61% ROA-54.28% Short Interest4.96M Perf Year-73.49%
Cash/sh1.09 P/C1.94 EPS next 5Y- ROE-112.29% 52W Range1.30 - 8.92 Perf YTD-29.90%
Dividend Est.- P/FCF- EPS past 5Y-48.08% ROI-60.32% 52W High-76.35% Beta1.92
Dividend TTM- Quick Ratio2.87 Sales past 5Y347.21% Gross Margin-47.40% 52W Low62.31% ATR (14)0.22
Dividend Ex-Date- Current Ratio2.87 EPS Y/Y TTM24.71% Oper. Margin-1921.30% RSI (14)40.24 Volatility9.65% 10.98%
Employees94 Debt/Eq3.09 Sales Y/Y TTM112.70% Profit Margin-1868.35% Recom1.00 Target Price11.00
Option/ShortYes / Yes LT Debt/Eq2.70 EPS Q/Q26.90% Payout- Rel Volume1.24 Prev Close2.13
Sales Surprise102.70% EPS Surprise-8.14% Sales Q/Q357.36% EarningsMay 06 BMO Avg Volume369.87K Price2.11
SMA20-8.21% SMA50-21.74% SMA200-27.19% Trades Volume459,595 Change-0.94%
Date Action Analyst Rating Change Price Target Change
May-25-23Resumed Jefferies Buy $18 → $15
Dec-08-22Initiated H.C. Wainwright Buy $11
Sep-23-22Initiated Chardan Capital Markets Buy $12
May-09-24 07:00AM
May-08-24 07:00AM
May-06-24 02:52PM
10:02AM Loading…
Apr-25-24 10:02AM
Apr-23-24 07:00AM
Apr-17-24 09:55AM
Apr-09-24 07:00AM
Apr-08-24 08:00AM
Apr-03-24 12:00PM
Mar-28-24 11:54PM
Mar-19-24 08:30AM
07:00AM Loading…
Mar-06-24 07:00AM
Jan-09-24 11:01PM
Jan-08-24 06:30AM
Jan-05-24 12:55PM
Jan-04-24 06:08PM
Jan-02-24 04:05PM
Dec-04-23 04:00PM
Nov-27-23 07:01PM
06:00AM Loading…
Nov-21-23 06:00AM
Nov-20-23 04:00PM
Nov-13-23 07:00AM
Nov-09-23 07:00AM
Nov-07-23 04:00PM
Nov-01-23 10:30AM
Oct-31-23 07:00AM
Oct-19-23 10:30AM
Oct-16-23 07:00AM
Oct-11-23 04:00PM
Oct-04-23 04:00PM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-26-23 07:00AM
Sep-25-23 04:00PM
Sep-21-23 04:00PM
Sep-11-23 06:30AM
Aug-29-23 07:00AM
Aug-05-23 08:05AM
Aug-03-23 05:15PM
Jul-20-23 07:39AM
Jul-18-23 09:43AM
Jul-12-23 07:00AM
Jul-03-23 11:20AM
Jun-22-23 09:18AM
Jun-14-23 11:48AM
Jun-08-23 11:49AM
Jun-06-23 12:13PM
Jun-01-23 07:00AM
May-31-23 08:30AM
May-25-23 09:55AM
May-16-23 06:00AM
May-10-23 07:34AM
May-09-23 09:55AM
May-04-23 08:35AM
Apr-27-23 07:00AM
Apr-13-23 06:33AM
Apr-06-23 04:01AM
Mar-30-23 07:00AM
Mar-17-23 03:35AM
Mar-03-23 05:01AM
Mar-01-23 08:35AM
Feb-23-23 07:00AM
Feb-10-23 04:11AM
Jan-17-23 07:00AM
Dec-08-22 01:24PM
Nov-28-22 09:55AM
Nov-17-22 07:00AM
Nov-15-22 07:00AM
Nov-11-22 09:55AM
Nov-10-22 05:57AM
Nov-08-22 07:00AM
Nov-03-22 07:00AM
Nov-02-22 07:00AM
Oct-27-22 07:00AM
Oct-12-22 07:00AM
Sep-26-22 07:00AM
Sep-06-22 07:00AM
Sep-01-22 07:00AM
Aug-04-22 07:00AM
Aug-03-22 07:00AM
Jul-14-22 04:05PM
Jul-11-22 11:03AM
Jun-30-22 11:32AM
Jun-23-22 07:00AM
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young Richard ADirectorJun 02 '23Sale8.005,00040,000739,118Jun 05 04:15 PM